The leber hereditary optic neuropathy treatment market forecast strong growth in the coming years and is expected to reach $0.53 billion in 2029 at a compound annual growth rate CAGR of 7.8%.

GenSight’s gene therapy treatment for patients living with Leber hereditary optic neuropathy (LHON) has demonstrated sustained efficacy and eyesight improvement over five years. France-based ...

A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to ...

An optic nerve that has an injury cannot be fixed, so usually, if there is vision loss from ischemic optic neuropathy, it is permanent. Those with badly damaged optic nerves usually can still see ...

More information: Rui Wang et al, MSC-mediated mitochondrial transfer restores mitochondrial DNA and function in neural progenitor cells of Leber's hereditary optic neuropathy, Science China Life ...

A groundbreaking study reveals that mesenchymal stem cells (MSCs) can restore mitochondrial function and DNA in neural progenitor cells of patients with Leber's Hereditary Optic Neuropathy (LHON).

Neurophth Therapeutics, Inc. (Neurophth), China's leading in-vivo gene therapy company for ophthalmic diseases, announced that the last patient has been enrolled in phase I/II clinical trial of Opvika ...

Non-arteritic ischemic optic neuropathy (NAION) is an eye condition that may restrict blood flow to the optic nerve. This results in painless, sudden-onset vision loss in one eye.

Leber hereditary optic neuropathy, also known as LHON or Leber optic neuropathy, is an inherited genetic condition. It often causes loss of central vision, starting in one eye and eventually ...

“Leber hereditary optic neuropathy (LHON) is a devastating disease of blindness, typically in young men in the prime of life, in which one eye becomes blind and at the same time, or within a few ...